205 related articles for article (PubMed ID: 36009013)
1. A Setmelanotide-like Effect at MC4R Is Achieved by MC4R Dimer Separation.
Reininghaus N; Paisdzior S; Höpfner F; Jyrch S; Cetindag C; Scheerer P; Kühnen P; Biebermann H
Biomolecules; 2022 Aug; 12(8):. PubMed ID: 36009013
[TBL] [Abstract][Full Text] [Related]
2. Structural analysis of setmelanotide binding to MC4R variants in comparison to wild-type receptor.
Hammad MM; Mohammad A; Alam-Eldin N; Madhu D; Al-Mulla F; Abu-Farha M; Abubaker J
Life Sci; 2022 Oct; 307():120857. PubMed ID: 35931197
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency.
Collet TH; Dubern B; Mokrosinski J; Connors H; Keogh JM; Mendes de Oliveira E; Henning E; Poitou-Bernert C; Oppert JM; Tounian P; Marchelli F; Alili R; Le Beyec J; Pépin D; Lacorte JM; Gottesdiener A; Bounds R; Sharma S; Folster C; Henderson B; O'Rahilly S; Stoner E; Gottesdiener K; Panaro BL; Cone RD; Clément K; Farooqi IS; Van der Ploeg LHT
Mol Metab; 2017 Oct; 6(10):1321-1329. PubMed ID: 29031731
[TBL] [Abstract][Full Text] [Related]
4. Melanocortin pathways: suppressed and stimulated melanocortin-4 receptor (MC4R).
Hainer V; Aldhoon Hainerová I; Kunešová M; Taxová Braunerová R; Zamrazilová H; Bendlová B
Physiol Res; 2020 Sep; 69(Suppl 2):S245-S254. PubMed ID: 33094623
[TBL] [Abstract][Full Text] [Related]
5. Differential Signaling Profiles of MC4R Mutations with Three Different Ligands.
Paisdzior S; Dimitriou IM; Schöpe PC; Annibale P; Scheerer P; Krude H; Lohse MJ; Biebermann H; Kühnen P
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32059383
[TBL] [Abstract][Full Text] [Related]
6. Insights into the Allosteric Mechanism of Setmelanotide (RM-493) as a Potent and First-in-Class Melanocortin-4 Receptor (MC4R) Agonist To Treat Rare Genetic Disorders of Obesity through an in Silico Approach.
Falls BA; Zhang Y
ACS Chem Neurosci; 2019 Mar; 10(3):1055-1065. PubMed ID: 30048591
[TBL] [Abstract][Full Text] [Related]
7. MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency.
Clément K; Biebermann H; Farooqi IS; Van der Ploeg L; Wolters B; Poitou C; Puder L; Fiedorek F; Gottesdiener K; Kleinau G; Heyder N; Scheerer P; Blume-Peytavi U; Jahnke I; Sharma S; Mokrosinski J; Wiegand S; Müller A; Weiß K; Mai K; Spranger J; Grüters A; Blankenstein O; Krude H; Kühnen P
Nat Med; 2018 May; 24(5):551-555. PubMed ID: 29736023
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological chaperone action in humanized mouse models of MC4R-linked obesity.
René P; Lanfray D; Richard D; Bouvier M
JCI Insight; 2021 Feb; 6(4):. PubMed ID: 33434184
[TBL] [Abstract][Full Text] [Related]
9. Structures of active melanocortin-4 receptor-Gs-protein complexes with NDP-α-MSH and setmelanotide.
Heyder NA; Kleinau G; Speck D; Schmidt A; Paisdzior S; Szczepek M; Bauer B; Koch A; Gallandi M; Kwiatkowski D; Bürger J; Mielke T; Beck-Sickinger AG; Hildebrand PW; Spahn CMT; Hilger D; Schacherl M; Biebermann H; Hilal T; Kühnen P; Kobilka BK; Scheerer P
Cell Res; 2021 Nov; 31(11):1176-1189. PubMed ID: 34561620
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials.
Clément K; van den Akker E; Argente J; Bahm A; Chung WK; Connors H; De Waele K; Farooqi IS; Gonneau-Lejeune J; Gordon G; Kohlsdorf K; Poitou C; Puder L; Swain J; Stewart M; Yuan G; Wabitsch M; Kühnen P;
Lancet Diabetes Endocrinol; 2020 Dec; 8(12):960-970. PubMed ID: 33137293
[TBL] [Abstract][Full Text] [Related]
11. Melanocortin receptor 4 deficiency affects body weight regulation, grooming behavior, and substrate preference in the rat.
Mul JD; van Boxtel R; Bergen DJ; Brans MA; Brakkee JH; Toonen PW; Garner KM; Adan RA; Cuppen E
Obesity (Silver Spring); 2012 Mar; 20(3):612-21. PubMed ID: 21527895
[TBL] [Abstract][Full Text] [Related]
12. MC4R variants modulate α-MSH and setmelanotide induced cellular signaling at multiple levels.
Rodríguez Rondón AV; Welling MS; van den Akker ELT; van Rossum EFC; Boon EMJ; van Haelst MM; Delhanty PJD; Visser JA
J Clin Endocrinol Metab; 2024 Apr; ():. PubMed ID: 38567654
[TBL] [Abstract][Full Text] [Related]
13. Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment.
Ayers KL; Glicksberg BS; Garfield AS; Longerich S; White JA; Yang P; Du L; Chittenden TW; Gulcher JR; Roy S; Fiedorek F; Gottesdiener K; Cohen S; North KE; Schadt EE; Li SD; Chen R; Van der Ploeg LHT
J Clin Endocrinol Metab; 2018 Jul; 103(7):2601-2612. PubMed ID: 29726959
[TBL] [Abstract][Full Text] [Related]
14. Activation of MAPK by inverse agonists in six naturally occurring constitutively active mutant human melanocortin-4 receptors.
Mo XL; Tao YX
Biochim Biophys Acta; 2013 Dec; 1832(12):1939-48. PubMed ID: 23791567
[TBL] [Abstract][Full Text] [Related]
15. Signal pathway analysis of selected obesity-associated melanocortin-4 receptor class V mutants.
Sharma S; Thibodeau S; Lytton J
Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165835. PubMed ID: 32423884
[TBL] [Abstract][Full Text] [Related]
16. Melanocortin-4 receptor complexity in energy homeostasis,obesity and drug development strategies.
Fatima MT; Ahmed I; Fakhro KA; Akil ASA
Diabetes Obes Metab; 2022 Apr; 24(4):583-598. PubMed ID: 34882941
[TBL] [Abstract][Full Text] [Related]
17. Structure reveals the activation mechanism of the MC4 receptor to initiate satiation signaling.
Israeli H; Degtjarik O; Fierro F; Chunilal V; Gill AK; Roth NJ; Botta J; Prabahar V; Peleg Y; Chan LF; Ben-Zvi D; McCormick PJ; Niv MY; Shalev-Benami M
Science; 2021 May; 372(6544):808-814. PubMed ID: 33858992
[TBL] [Abstract][Full Text] [Related]
18. Melanocortin-4 Receptor Signalling: Importance for Weight Regulation and Obesity Treatment.
Kühnen P; Krude H; Biebermann H
Trends Mol Med; 2019 Feb; 25(2):136-148. PubMed ID: 30642682
[TBL] [Abstract][Full Text] [Related]
19. Setmelanotide: First Approval.
Markham A
Drugs; 2021 Feb; 81(3):397-403. PubMed ID: 33638809
[TBL] [Abstract][Full Text] [Related]
20. Setmelanotide, a Novel, Selective Melanocortin Receptor-4 Agonist Exerts Anti-inflammatory Actions in Astrocytes and Promotes an Anti-inflammatory Macrophage Phenotype.
Kamermans A; Verhoeven T; van Het Hof B; Koning JJ; Borghuis L; Witte M; van Horssen J; de Vries HE; Rijnsburger M
Front Immunol; 2019; 10():2312. PubMed ID: 31636637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
